NCT02237924View on ClinicalTrials.gov

Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2021

Study Completion Date

January 31, 2022

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG

endostar

Endostar 7.5mg / m2, 2 cycles of continuous intravenous pumping for ten days,and 2 cycles of maintenance therapy after radiotherapy

DRUG

DDP

DDP:100mg/m2 for 2-3 cycles

RADIATION

IMRT

IMRT:70-74Gy for 2-3 cycles

Trial Locations (1)

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors

lead

First Affiliated Hospital of Guangxi Medical University

OTHER

NCT02237924 - Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter